Sales & Marketing News | pharmaphorum

News

Daiichi exits OTC, with $1.55bn unit sale to Suntory

Daiichi Sankyo has agreed to sell its consumer health unit to food and beverage giant Suntory, following a well-trodden path for big pharma companies.

News

FDA seeks safety data for Lilly's oral GLP-1 Foundayo

The FDA has laid out post-marketing safety testing requirements for Lilly's weight-loss pill Foundayo, including clinical trials.

News

Novo Nordisk partners OpenAI on R&D "transformation"

Seeking an R&D edge, Novo Nordisk has become the latest big pharma group to forge an alliance with tech giant OpenAI.

News

Travere claims first FDA OK in rare kidney disease FSGS

Shrugging off an earlier phase 3 disappointment, Travere’s Filspari has become the first FDA-approved treatment for rare kidney disease FSGS.

News

FDA hands another rejection to Replimune's melanoma therapy

Replimune has had its advanced melanoma treatment RP1 turned down by the FDA for a second time, prompting job losses.

News

Senju launches first-in-class dry eye disease drug in Japan

Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.

Daiichi exits OTC, with $1.55bn unit sale to Suntory

FDA seeks safety data for Lilly's oral GLP-1 Foundayo

Novo Nordisk partners OpenAI on R&D "transformation"

Travere claims first FDA OK in rare kidney disease FSGS

FDA hands another rejection to Replimune's melanoma therapy

Senju launches first-in-class dry eye disease drug in Japan

FDA issues warning letters to five unapproved GLP-1 websites

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks